Concepedia

Gregory Monohan

GM

Statistics

Publications

7

Citations

237

H-Index

7

Active since

2015

Affiliations

University of Kentucky(Current)

Markey Cancer Center

AbbVie (United States)

Huntsman Cancer Institute

University of Alabama at Birmingham

Gregory Monohan is an author at University of Kentucky specializing in medicine, chemotherapy, and hematologic malignancy therapy.

Publications per year

2015–2021

7

Publications

7

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Luciano J. Costa, Faith E. Davies, Gregory Monohan et al. · Blood Advances · 2021 · 87 citations · Full text

, , +16

Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting

Hayder Saeed, Ryan Woods, Joshua Lester et al. · International Journal of Hematology · 2015 · 50 citations

, , +14

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Kevin R. Kelly, Jonathan W. Friedberg, Steven Park et al. · Clinical Cancer Research · 2018 · 36 citations · Full text

, , +17

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Luciano J. Costa, Edward A. Stadtmauer, Gareth J. Morgan et al. · Journal of Clinical Oncology · 2018 · 21 citations

, , +14

Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Luciano J. Costa, Edward A. Stadtmauer, Gareth J. Morgan et al. · Blood · 2018 · 18 citations

, , +16

1–5 of 7